# Analytical Immunopharmacology

> **NIH NIH U19** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2023 · $82,250

## Abstract

PROJECT SUMMARY – CORE A
The Analytical Immunopharmacology Core (Core A) is designed to meet the specific drug and biologic
therapeutic development needs of each of the U19 Research Projects and at the same time draw on the strength
of the existing City of Hope Comprehensive Cancer Center (COHCCC) cores without unnecessary duplication
of services. Core A will work closely and synergistically with COHCCC cores, as well as with the U19
Administrative Core and the Molecular Profiling and Bioinformatics Core (Core B) to provide exceptional support
for all of the proposed Research Projects and inter-U19 collaborations. The overarching goals of Core A are to
assist the Glioblastoma Therapeutics Network (GTN) U19 Project Leaders with pharmacokinetic (PK) and
pharmacodynamic (PD) correlative studies performed in support of the proposed clinical trials. The work will be
accomplished by leveraging the Core’s significant expertise in intracerebral microdialysis (ICMD), analytical
chemistry, and analytical immunochemistry, as well as its access to state-of-the-art instrumentation. The overall
purpose will be achieved through the following Specific Aims:
Aim 1. Provide conceptual and analytical support to U19 investigators for correlative neuro-PK analyses
(e.g., analysis of drugs and metabolites in the CNS). Support provided by Core A to U19 investigators under
this aim will include all aspects of ICMD neuro-PK studies, including experimental design, analytical method
development, sample analysis, and final interpretation of the data. Core A is staffed by highly trained personnel
and equipped with analytical instrumentation that will be ideal for the quantitative analyses of small molecules
(e.g., LC-MS/MS and ICP-MS/MS).
Aim 2. Provide conceptual and analytical support to U19 investigators for their correlative neuro-PD
analyses (e.g., analysis of biomarkers of drug response in the CNS). Support provided by Core A to U19
investigators under this aim will include all aspects of ICMD neuro-PD studies, including experimental design,
analytical method development, sample analysis, and final interpretation of the data. Core A will provide a
spectrum of immunoassay platforms (e.g., Luminex and ELISA) in the context of ICMD neuro-PD studies in
support of the proposed clinical trials.

## Key facts

- **NIH application ID:** 10696183
- **Project number:** 5U19CA264512-03
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** TIMOTHY W SYNOLD
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $82,250
- **Award type:** 5
- **Project period:** 2021-09-13 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10696183

## Citation

> US National Institutes of Health, RePORTER application 10696183, Analytical Immunopharmacology (5U19CA264512-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10696183. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*